Publications Update # 61
Anti-emetic guidelines, Immunotherapy with the anti-angiogenesis blockade, how to present in front of an audience that knows more than you and LACC's long term outcomes
Publications Update
Publications Update # 60
PARP inhibitors in ovarian cancer and recent withdrawals, Current FDA indications, Platinum resistant ovarian cancer management, SIENDO trial
Publications Update # 59
Secondary debulking tutorial and data, genetic testing in ovarian cancer, Adam Grant interviewing Airbnb CEO Brian Chesky - a company is not a family
Publications Update # 58
Soft skills or real skills, GOG 238, Selinexor in endometrial cancer, complications after radical hysterectomy
Publications Update # 57
Drug shortages, RUBY/GY018 decision aid, TOTEM trial and cancer statistics
Publications Update # 56
Financial planning checklist, MITO-23 clinical trial, reducing surgical site infections by using a wound protector and reducing hernia rates using small-bite closure
Publications Update # 55
Molecular testing in endometrial cancer. Checkmate 358 trial cervical cancer
Publications Update # 54
The investment answer, surrogate endpoints in oncology, GOG-279 and A18 in cervical cancer
Publications Update # 53
HER-2 testing in gynecologic cancers, prognostic role of ITCs in low-grade endometrial cancer, primary cytoreduction in ovarian cancer.
Publications Update # 52
Becoming G.O.A.T by adopting a goat's mentality, 3+3 clinical trial design, vulvar cancer groin node management and the risk of ovarian metastasis in endometrial cancer patients less than 50